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The largest global outbreak of extensively drug-resistant (XDR) tuberculosis (TB) was iden-
tified in Tugela Ferry, KwaZulu-Natal (KZN), South Africa in 2005. The antecedents and tim-
ing of the emergence of drug resistance in this fatal epidemic XDR outbreak are unknown,
and it is unclear whether drug resistance in this region continues to be driven by clonal
spread or by the development of de novo resistance. A whole genome sequencing and drug
susceptibility testing (DST) was performed on 337 clinical isolates ofMycobacterium tubercu-
losis (M.tb) collected in KZN from 2008 to 2013, in addition to three historical isolates, one of
which was isolated during the Tugela Ferry outbreak. Using a variety of whole genome
comparative approaches, 11 drug-resistant clones of M.tb circulating from 2008 to 2013
were identified, including a 50-member clone of XDR M.tb that was highly related to the
Tugela Ferry XDR outbreak strain. It was calculated that the evolutionary trajectory fromcal School,
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the start of the antibiotic era. It was also observed that frequent de novo evolution of MDR
and XDR was present, with 56 and 9 independent evolutions, respectively. Thus, ongoing
amplification of drug-resistance in KwaZulu-Natal is driven by both clonal spread and de
novo acquisition of resistance. In drug-resistant TB, isoniazid resistance was overwhelm-
ingly the initial resistance mutation to be acquired, which would not be detected by current
rapid molecular diagnostics that assess only rifampicin resistance.
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